Compare Bristol-Myers Squibb Co (BMY) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Essex Property Trust, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Essex Property Trust, Inc. trades at $297.8 (market cap $19.16B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.1× Essex Property Trust, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | ESS | |
|---|---|---|
Market Cap | $116.30B | $19.16B |
Sector | Health | Real Estate |
52-Week High | $62.37 | $298.33 |
52-Week Low | $42.60 | $239.61 |
Enterprise Value | $152.24B | $25.88B |
Dividend Yield | 4.42% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ESS trades at $297.48, up 1.34% today, near its consensus price target of $294.25. The stock shows bullish technical momentum with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index. Fundamentals remain solid with $1.89B revenue and a 30.03% net income margin in 2025.
Outlook is cautiously optimistic given analyst consensus leaning toward Hold (52.17%) despite recent beats. Key opportunities include AI-driven rental demand in West Coast markets and a sustainable dividend. Risks involve high debt levels (debt-to-asset ratio of 51.92% in 2024) and potential economic sensitivity. The stock offers moderate upside if earnings momentum continues but requires monitoring of leverage and regional market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
